 Date: 2015-07-30 04:30:57Chronic lower respiratory diseases Respiratory therapy Respiratory diseases Asthma Chronic obstructive pulmonary disease Chronic condition Sanofi Bronchial hyperresponsiveness Obstructive lung disease Firestone Institute for Respiratory Health | |  ZAI Lab announces a global licensing agreement with Sanofi for two novel compounds in chronic respiratory diseases ShanghaiZAI Lab Limited (ZAI Lab), an innovative biotech company in China, announced today
Add to Reading ListSource URL: www.zailaboratory.comDownload Document from Source Website File Size: 359,53 KBShare Document on Facebook
|
